Clinician and patient understanding and access considerations represent the most significant hurdles inhibiting the uptake of biosimilars for inflammatory conditions.
Laurie Toich, Assistant Editors
Advertisement
Articles by Laurie Toich, Assistant Editors
Advertisement
Latest Updated Articles
- Biosimilars May Change the Treatment Landscape for Inflammatory Diseases
Published: September 11th 2017 | Updated:
- Biosimilars May Change the Treatment Landscape for Inflammatory Diseases
Published: September 21st 2017 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Five-Year NATALEE Data Show Ribociclib Improves Outcomes in High-Risk HR+/HER2– Early Breast Cancer
2
Abemaciclib Provides Long-Term Survival Benefit in High-Risk Early Breast Cancer
3
Durvalumab Plus Chemotherapy Sets New Standard in Resectable Gastric and GEJ Cancer
4
Cholesterol-HDL-Glucose Index Linked to Type 2 Diabetes Prevalence in Adults
5
